Radspherin is under clinical development by Oncoinvent and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II drugs for Peritoneal Cancer have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Radspherin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Radspherin overview
Radspherin, is under development for the treatment of metastatic cancers including peritoneal carcinomatosis originating from ovarian cancer, fallopian cancer, peritoneal cancer and colorectal cancer. It constitutes a monoclonal antibody OI-3 conjugated to a radioisotope or toxin. The drug candidate is a suspension of inorganic alpha-emitting radioactive microspheres and administered as intraperitoneal injection. It acts by targeting CD146 antigen.
See Also:
Oncoinvent overview
Oncoinvent (Oncoinvent) is a pharmaceutical company that focuses on developing radiopharmaceutical products to treat cancer patients. The company’s lead product candidate, Radspherin is an alpha-emitting radioactive microsphere for injection to treat metastatic cancers in body cavities. Its product pipeline comprises radiotherapeutic, radio-immunotherapeutic, and immunotherapeutic drugs to treat various solid cancers. The company is also investigating Radspherin in Phase I clinical stage for the treatment of peritoneal carcinomatosis from ovarian and colorectal cancer. Oncoinvent is headquartered in Oslo, Norway.
For a complete picture of Radspherin’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
